Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Eur J Clin Microbiol Infect Dis ; 33(1): 123-33, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24026862

RESUMEN

Persistent high-risk human papillomavirus (HR-HPV) infection is the key event in the progression of HPV lesions, and more data are urgently needed on asymptomatic oral HPV infections in men. Asymptomatic fathers-to-be (n = 131, mean age 28.9 years) were enrolled in the cohort, sampled by serial oral scrapings at baseline and at 2-month, 6-month, 12-month, 24-month, 36-month, and 7-year follow-up visits to accomplish persistent and cleared HPV infections. HPV genotyping was performed using nested PCR and Multimetrix® assay. Covariates of persistent and cleared oral HPV infections were analysed using generalised estimating equation (GEE) and Poisson regression. Altogether, 17 HPV genotypes were detected in male oral mucosa point prevalence, varying from 15.1 % to 31.1 %. Genotype-specific HPV persistence was detected in 18/129 men the mean persistence time ranging from 6.0 to 30.7 months. History of genital warts decreased (p = 0.0001; OR = 0.41, 95 % CI 0.33-0.51) and smoking increased (p = 0.033, OR = 1.92, 95 % CI 1.05-3.50) the risk of persistent species 7/9 HPV infections. Of the 74 HPV-positive men, 71.6 % cleared their infection actuarial and crude clearance times, varying between 1.4 and 79.6 months. No independent predictors were identified for species 7/9 clearance. At the last follow-up-visit, 50.1 % of the fathers had oral mucosal changes, correlating only with smoking (p = 0.046). To conclude, most of the persisting oral infections in males were caused by HPV16. Smoking increased while previous genital warts decreased oral HR-HPV persistence. No predictors of HR-HPV clearance were disclosed.


Asunto(s)
Portador Sano/epidemiología , Portador Sano/virología , Mucosa Bucal/virología , Papillomaviridae/aislamiento & purificación , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/virología , Fumar/efectos adversos , Adulto , Estudios de Cohortes , ADN Viral/genética , Estudios de Seguimiento , Genotipo , Técnicas de Genotipaje , Humanos , Masculino , Papillomaviridae/clasificación , Papillomaviridae/genética , Reacción en Cadena de la Polimerasa , Estudios Prospectivos , Factores de Tiempo
2.
Clin Exp Dermatol ; 37(8): 897-903, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22924518

RESUMEN

BACKGROUND: Tacrolimus ointment has shown efficacy in treating T-cell-mediated inflammatory oral mucosal diseases, including lichen planus. However, the safety of topical tacrolimus has been questioned, based on its possible association with malignant transformation. AIM: To evaluate the safety aspects of tacrolimus in a three-dimensional in vitro model of oral mucosa containing both multilayered epithelium and connective tissue (raft culture). METHODS: Raft cultures mimicking oral mucosa were topically exposed to tacrolimus, and the effects on cell proliferation and adhesion, epidermal growth factor receptors (EGFR, ERBB2, ERBB3, ERBB4), and apoptosis were evaluated with immunohistochemistry and terminal dUTP nick-end labelling, respectively. Results. The epithelium of the cultures was found to be slightly thinner, but no changes in cell proliferation or adhesion, apoptosis, or expression of epidermal growth factor receptors were detected. CONCLUSIONS: Our results suggest that short-term topical tacrolimus exposure of in vitro constructed oral mucosa does not induce changes in a number of factors known to be involved in malignant transformation.


Asunto(s)
Inmunosupresores/farmacología , Mucosa Bucal/efectos de los fármacos , Tacrolimus/farmacología , Apoptosis/efectos de los fármacos , Adhesión Celular/efectos de los fármacos , Técnicas de Cultivo de Célula/métodos , Proliferación Celular/efectos de los fármacos , Factor de Crecimiento Epidérmico/efectos de los fármacos , Humanos , Inmunohistoquímica , Inmunosupresores/efectos adversos , Etiquetado Corte-Fin in Situ/métodos , Tacrolimus/efectos adversos , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...